Metagenomi, Inc. Investors Key Actions Ahead
Investors should take note of significant developments regarding their holdings in Metagenomi, Inc. (NASDAQ: MGX). Legal actions are ongoing, and understanding your rights is essential for all shareholders. Recently, a noted investor rights law firm has issued an alert concerning vital deadlines for affected investors.
What You Need to Know About the Lawsuit
A securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors who purchased or acquired shares of Metagenomi. This lawsuit centers around allegations of misleading statements made by the company regarding its collaboration with Moderna, in a partnership established through a Strategic Collaboration and License Agreement on October 29, 2021. The allegations stem from misleading representations about the scope and potential of the agreement.
Key Date for Investors
For shareholders, the date to keep in mind is November 25, 2024. This is the deadline to file a lead plaintiff motion. Being a lead plaintiff involves guiding the litigation process on behalf of other class members. However, participation in the class does not require you to take on this role. If you prefer to do nothing, you may remain an absent class member.
Steps to Protect Your Rights
If you owned Metagenomi shares during the initial public offering that took place between February 9 and 13, 2024, you should consider your legal options. Investors who partake in this process can seek potential recovery for any financial losses incurred due to the alleged misrepresentations. Additionally, it’s noteworthy that all legal representation is provided on a contingency fee basis, meaning investors will not need to pay upfront fees or expenses.
About the Legal Firm Involved
Bernstein Liebhard LLP is the law firm at the forefront of this lawsuit, bringing decades of experience in handling investor rights cases. Since being established in 1993, the firm has had extensive success, recovering over $3.5 billion for its clients, including both individual investors and significant pension funds. Their firm has gained recognition by The National Law Journal and The Legal 500 for its outstanding results in litigation.
Investor Relations Contact
For those looking to get more information, Peter Allocco, the Investor Relations Manager at Bernstein Liebhard LLP, is available for inquiries. He can be reached directly at (212) 951-2030. Engaging with the firm's representatives can provide clarity on any legal questions or concerns you may have regarding the ongoing lawsuit.
Frequently Asked Questions
What does the lawsuit against Metagenomi, Inc. involve?
The lawsuit claims that Metagenomi made misleading statements about its partnership with Moderna, resulting in financial losses for shareholders.
What are the important dates for investors?
Investors must file a lead plaintiff motion by November 25, 2024, to be represented in the class action lawsuit.
How can I participate in the lawsuit?
If you owned Metagenomi shares during the specified IPO period, you can discuss your options with the law firm involved to understand how to proceed.
Is there a fee for participating in the lawsuit?
All representation by Bernstein Liebhard LLP is on a contingency fee basis, meaning you won't pay any fees unless there is a recovery.
Who can I contact for more information?
For additional information, you can contact Peter Allocco at (212) 951-2030 or reach out via their official website.
